BCIQ Profiles

Company Profile Report

Canakinumab reduces lung cancer mortality, headed for Phase III

Novartis AG (NYSE:NVS; SIX:NOVN) said canakinumab (ACZ885) significantly reduced lung cancer incidence and associated mortality vs. placebo in the Phase III CANTOS cardiovascular outcomes trial in patients with a prior heart attack and inflammatory atherosclerosis. Spokesperson Eric Althoff told BioCentury

Read the full 401 word article

How to gain access

Continue reading with a
two-week free trial.